Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP4 | P49662 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | CASP9 | P55211 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PARL | Q9H300 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15069163 | 1.00 | BRD4 (0.52) | BRD4HTR6L3MBTL1LMNACASP1 | |
| SCHEMBL15069625 | 0.90 | BRD4 (0.49) | BRD4HTR6L3MBTL1LMNAMAPT | |
| SCHEMBL31073711 | 0.86 | BRD4 (0.54) | BRD4 | |
| SCHEMBL15069411 | 0.86 | BRD4 (0.55) | BRD4 | |
| SCHEMBL31395498 | 0.86 | BRD4 (0.55) | BRD4 | |
| SCHEMBL15069178 | 0.86 | BRD4 (0.52) | BRD4HTR6L3MBTL1LMNAMAPT | |
| SCHEMBL31073867 | 0.86 | BRD4 (0.49) | BRD4HTR6LMNAMAPTMEN1 | |
| SCHEMBL20384519 | 0.84 | BRD4 (0.56) | BRD4 | |
| SCHEMBL15069384 | 0.84 | BRD4 (0.54) | BRD4 | |
| SCHEMBL31469056 | 0.83 | BRD4 (0.61) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702022-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | Halda Therapeutics Opco, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| CN-119684283-A | Pyrrolo [2,3-c ] pyridines and use thereof | 山东新时代药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024211684-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024193527-A1 | PYRROLO[2,3-C]PYRIDINE COMPOUND AS BROMODOMAIN INHIBITOR | 山东新时代药业有限公司 | 2024-09-26 | — | — | WO | disclosed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023059581-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, BRDT, BICRA | BRD4 1/4885HTR6 1278/4885L3MBTL1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.